Lionco Pharm Grp Co Ltd (603669.SS) stock: key figures, P/E, revenue and dividend

Health Care · Pharmaceuticals · China · ISIN CNE1000022R8

Price
5.59 CNY
Market cap
4.03 bn CNY
P/E (2025)
–
P/S (2025)
12.50
Dividend yield
0.00 %
Net margin
-59.92 %
Return on equity (ROE)
-31.15 %
Return on assets (ROA)
-17.46 %

Lionco Pharm Grp Co Ltd financials

Fiscal year20242025
Revenue379.78 m CNY322.48 m CNY
Gross profit173.26 m CNY140.97 m CNY
Operating income-128.77 m CNY-93.26 m CNY
EBIT-100.28 m CNY-172.32 m CNY
Net income-130.76 m CNY-193.24 m CNY
Diluted EPS – continuing operations-0.18 CNY-0.27 CNY

Full history since 2011, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Lionco Pharm Grp Co Ltd

Lionco Pharmaceutical Group Co.,Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical products and medical services in China. It offers chemical and prescription drugs for nutrition, antimicrobial, antiviral, digestive, cardiovascular, cerebrovascular, detoxification, anti-tumor, anti-infective drugs, and other applications. Lionco Pharmaceutical Group Co.,Ltd. was founded in 2003 and is based in Shannan, China.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 10.11.2026. Details in the risk notice.